Turning Point Therapeutics - TPTX Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TPTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TPTX, but not buy additional shares or sell existing shares.
View TPTX analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1-year target prices for Turning Point Therapeutics' stock. Their TPTX share price forecasts range from $45.00 to $116.00. On average, they expect the company's share price to reach $78.22 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for TPTX or view top-rated stocks among Wall Street analysts.

Turning Point Therapeutics' stock was trading at $47.70 at the beginning of 2022. Since then, TPTX shares have increased by 59.4% and is now trading at $76.01.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our TPTX earnings forecast.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) posted its quarterly earnings results on Monday, August, 8th. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.78) by $0.70. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $2.27 million. The firm's quarterly revenue was down 97.7% on a year-over-year basis. During the same period last year, the business earned ($1.14) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (3.30%), Alpine Associates Management Inc. (2.07%), Price T Rowe Associates Inc. MD (1.91%), Federated Hermes Inc. (1.83%), Goldman Sachs Group Inc. (1.82%) and FMR LLC (1.42%). Insiders that own company stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Paolo Tombesi, Siegfried Reich and Yi Larson.
View institutional ownership trends.

Shares of TPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TPTX stock can currently be purchased for approximately $76.01.

Turning Point Therapeutics (NASDAQ:TPTX) has a market capitalization of $3.81 billion and generates $30.83 million in revenue each year. The company earns $-236,550,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis.

The company employs 250 workers across the globe.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.tptherapeutics.com. The company can be reached via phone at (858) 926-5251 or via email at jim.mazzola@tptherapeutics.com.